HU229833B1 - Epothilone d production process, and its use as cytostatic as well as phytosanitary agents - Google Patents
Epothilone d production process, and its use as cytostatic as well as phytosanitary agents Download PDFInfo
- Publication number
- HU229833B1 HU229833B1 HU0000497A HUP0000497A HU229833B1 HU 229833 B1 HU229833 B1 HU 229833B1 HU 0000497 A HU0000497 A HU 0000497A HU P0000497 A HUP0000497 A HU P0000497A HU 229833 B1 HU229833 B1 HU 229833B1
- Authority
- HU
- Hungary
- Prior art keywords
- epothilone
- spotilon
- brain
- experiment
- polymerization
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 4
- 239000000824 cytostatic agent Substances 0.000 title description 2
- 230000001085 cytostatic effect Effects 0.000 title description 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- XOZIUKBZLSUILX-UKMAFROXSA-N epothilone d Chemical compound O1C(=O)C[C@@H](O)C(C)(C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)CCC\C(C)=C/C[C@@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-UKMAFROXSA-N 0.000 title 1
- 229930013356 epothilone Natural products 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims 3
- 238000002474 experimental method Methods 0.000 claims 3
- 238000012404 In vitro experiment Methods 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 claims 1
- 238000011887 Necropsy Methods 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 150000003883 epothilone derivatives Chemical class 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000003463 adsorbent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 5
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 5
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- -1 -HCO # -NCS or -X.) Chemical class 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241001532577 Sorangium Species 0.000 description 1
- 241000862997 Sorangium cellulosum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Microbiology (AREA)
- Dentistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- Oncology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Silicon Polymers (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Epoxy Compounds (AREA)
Description
(57) Kivonat
A bejelentés D epotilon előállítását írja le Sorangium cellulosum DSM 6773 törzsből kiindulva, melyet adszorbens gyanta jelenlétében tenyésztenek, az adszorbens gyantát a tenyészetből eltávolítják, víz/metanol eleggyel mossák, metanollal eluálják, az eluátumot betöményítve nyers extraktumot kapnak, melyet etil-acetáttal extrahálnak, az extraktumot betöményítik, metanol és hexán között megosztják, a metanolos fázist betöményítve raffinátumot kapnak, a koncentrátumot Sephadex oszlopon frakcionálják, a mikroorganizmus által termelt metabolitokat tartalmazó frakciót C18 típusú reverz fázisú oszlopon metanol/víz eleggyel kromatografálják, a D epotilont tartalmazó frakciót elkülönítik.
1, ábra
A találtóny - egyik Mogvalósltási módja eljárás D apotilon előállítására oly módon, hagy (a) Sorangium oellulosam bők 8773 jelű törzset önmagában ismert módon adsrorbans gyanta jelenlétében tenyésztünk, (fe) az adszorbens gyantát a tenyészetből eltávolítjuk «Is viz/betanol alaggyal mossuk, fc) a mosott adszorbens gyantát metanollal alnáljok, és őz aluétum.oé botóményitve nyers eatrakéumot kapunk/ (d) a kapott koncentrátumot etii-acatátéal extraháljuk/ az eatraktumot feetöményXtják és metanol és bénán között magosatjuk# (e) a metanolon fázist betóményitze raf£Inátumot kapunk, és a kenoantrátumot Saphsdex ossiopon frakolonáljuk, (i) az alkalmazott mikroorganizmus által termált metabolitokat tartalmasé frakóiőt kapunk,
Cg) a kapott frakciót CXá ttpasű rovarz fázisú oszlopon metanol/víz elággyal krometografáljuk, és szekvenciálison egy A epotilont tartalmasé első frakciót és “ egy fe egeim k\u tartakomse oaaodix Hakeitt ™ agy első további epotilont (C apótiIon) tartalmasó ha rmadlk f rako1ót és ~ egy második további epotilont(b apóéiIon) tártaiba tó negyedik frakciót kapunk, és (h) a második további frakció epotiIonját <Ö epotilon) elkülönít jók.
& találmány tárgya továbbá ar alábbi képletü b epetilom
D epotilóó a ™ CHS
B vegyöiet tapasztalati képlete Ο«Κ^0§5 és te 1, Táblázatban megadott ''H-ée *SONMR spektrumai j ell emez hat <b
A D epei. Ilon felhasználható as alábbi 1 képleté vegyületek eléáilltásához# melyek a bk>A~9?/X9 Oáá sz. asabedaltd létráéban ismertetett származék képzési módéterekkel állíthatók elb.
A fenti X» képletben:
R «* R,, ;
R\ R:sf RC R% Rs - H, C©.-elk.ilf Cx~«~&ci 1-ben zoil #
Ca-^-tríaikíl-szilii# benzil# fenil#
Cx-s-alkeni·”#
Cp-aXkil-# hidroxi- és hal o génnel, helyettesített benzil vagy fenilí ahol az R* ~ R^ gyökök közül tette -jCH·?)» csoportot is alkothat# amelyben n jelentése 1 és 6 közötti szám# és a gyökökben lévő alkil- vagy acil-csoportöK egyenes vagy elágazó láncnak?
Y és 1 jelentése azonos vagy különböző lehet és egymástól függetlenül hidrogénatomot# halogénatomot (pl- F# Cl#- Ba vagy 1) # nszaadohalogént (pl. -HCO# -NCS vagy -Xcsoportot.}, 0B~# O~ { Cs.*} ~acil~# 0~ { C?-s) ~ai ki 1 ~ vagy 0benzöil-esoportpt képviselhet, Y és 2 jelentheti egy epoxid oxigénatomját is# mivel oltalmi igényünk az A és B epotilonra nem terjed ki# vagy egy C«C kettős kötés egyik € ~ C köt é s é t a 1 ko t j á k, & 12#·13·~kettős kötés szelektíven - hidrogénezhető.# például katalitikusén vagy diiminnel# ily módon olyan 1 képletü vegyületet kapunk# amelynek képletében Y ~ 2 *« H; vagy ~ epoxiddá alakítható# például dimetil-dioxiránnal vagy egy persawal# ily módon olyan 1 képletü vegyületet kapunk# amelynek képletében Y =» 2 - -0-, vagy dihalidokká# dipszeudohalidokká vagy diazidokká alakítható# ily módon olyan. 1 képletü vegyületet kapunk# amelynek képletében Y és i - Hal# p.szeudo~hal vagy B;;.
A találmány továbbá gyógyászati készítményekre külőnösen citosztatikumokra vonatkozik# amelyek D epotilont vagy epotiionnak egy vagy több szokásos hordozóanyággal és/vagy higitószerrel képetett kombinációiét tartalmazsák,
A találmányt az alábbi kiviteli példákkal rás zlet esebben is bemutatjuk.
D epotlXon
A, Az előállításhoz használt baktérlmi-törzs és &
SB~B~4£ 3S ö<2 », azahadalonfeen ieirtaknak belelnek meg.
a. 1 ap s 2 abada 1 ómba n és egy gyártó 700 I tér£ogatű
B. Blőállítás DSM 6773 tőrmel
1 tenyészetet az ismertetett módon tenyésztünk, fezmentálóberendezésben elhelyezet t, előállító közeget oltunk be vele, A közeg összetétele a: alábbi: 0,8 % keményítő, 0,2 % ssőlőcukor, 0,2 1 szójaliszt, 0,2 % élesztőkivonat, 0,1 % CaCls x 2X0, ö,“ % MgSÖ« x 7 H:í0, 8 mg/l Fe-EOTA, pH ~ 7,4 és kívánt esetbei 15 1 Ambrelíte XAD-16 adszorber gyanta- A fermentálás 30 1 hőmérsékleten 7-1Ö napig tart, a levegőztetést 0,1. NL/isr1 ~ rel végezzük. A rotáció sebességének kontrollálásával a pÖ2~t 30 %“on tartjuk.
C, Izolálás
Az adszorbens gyantát a tenyészettől 0,7 m2, 100 mesh. iyukméretö szörŐ alkalmazásával elválasztjuk, és az égy térfogatára számítva háromszoros mennyiségű, 2:1 arányú viz/metanol eleggyel mosassuk, hogy megszabadítsuk a poláros szennyeződésektől. Az ágy térfogatára számítva négyszeres mennyiségű metanollal történő eluálást követően nyers extraktumot kapunk# amelyet vákuumban a vizes fázis meg jozenésélg bogárólunk«
Ezt háromszor ugyanolyan mennyiségű etil™ acetátfal extraháljuk. A szerves fázist bepárolva 240 g nyers extraktumot kapunk# amelyet a lipofil szennyeződések leválasztása céljából metanol és heptán között megesztank. Az elegyek vákuumban bepároljak- Ily módon 180 g raffinátumot kapunk a metanolos fázisból# amit Sephadex LH~20 jelű oszlopon (20 x 100 cm# 20 mi/perc metanol) három részre frakcionálunk, Az epotilonokat a 240 - 300 perc retehciós idővel kioldódd frakció tartalmazza,# melynek ő'sszmennyisége 7.2 g. Az epotIlonok szétválasztása céljából a frakciót három részletben krőmatögrafáljak Idohroeorb RE-18 oszlopon <15 pm# 10 x 40 om-es oszlop# eluálószer: ISO ml/pere sebességgel átfolyatott# SS:3§ arányé metanol/víz elegy). Először az A és B# majd a € epotilon oldódik ki ss §0-95 perc), majd pedig a D epotilon 100-110 perc retenciós idővel„ Vákuumban történő bepárlés után valamennyi terméket szintélen olaj formájában kapjuk# ö#3 g hozammal.
1» Táblázati 0 epotilon *H~ és C-HMH adatai [b%] OMSO-ban, 300 MHt-en
D epotilon | |||
8 (ppp) | C atom | 8 (pp.e) | |
1 | 170,1 | ||
2-Ha | 2,35 | 2 | 33, 0 |
2-Hb | 2, 30 | 3 | 70,0 |
3-H | 4,1 0 | 4 | 53,2 |
3-OH | 5,08 | 5 | 217,4 |
6-H | 3,11 | 0 | 44,4 |
7-H | 3,40 | 7 | 75, 5 |
7-OH | 4,46 | 3 | .36, 3 |
S-H | 1,25 | 9 | 29,9 |
3~ Ha | Λ í i | 10 | 25, 9 |
9-Hb | 1,30 | 11 | 31, 8* |
10 -Ha | 1,14* | 12 | 130, 2 |
10-Hb | 1,35* | 13 | 120,3 |
11 -Ha | 1, 7 5 | 14 | 31,6* |
11-Hb | 2,10 | 15 | 76, 0 |
12-H | 16 | 137,2 | |
13-H | 5,08 | 1.7 | 119,2 |
14 -Ha | 2, 30 | 10 | 152,1 |
14-Hb | .2, 65 | 19 | 117, 7 |
1S~H | 5,29 | 20 | 164,3 |
17-H | 6,51 | 21 | IS, 9 |
I9-H | 7,35 | 22 | 19,7 |
21-Hs | 2, 65 | 23 | 22,5 |
22~K3 | 0, 90 | 24 | 16, 4 |
23~H3 | 1,19 | 25 | Λ $5 í 4 |
2 4-Hí | 1,07 | 26 | 22, 3 |
2S~B3 | 0,91 | 27 | 14, X |
.26-¾ | 1 ? 03 | ||
27-¾ | 2,11 |
* felcserélhető asssi^náeió ··*
Λ találmány eserinti D epotilont és at l^S, dseaehaeonllt.6 példa szerinti A, B, C, E és F epet Hont sejt tenyéeseteken /2.táblásat/ és a pollMerisáció elősegítésére /3, táblázat/ testteltük.
2. Táblázat;
Rpctilsm | w 192 | & SO? xto-so | »'X \x 67? (ng/ssll | 1·.' Sál | SOS | s: S 2 3 |
tgér kőfcőssöv&tl .sejt t 92$ | 1 | 1. | 100 | 20 | 20 | 1,5 |
Rüssáft daqsmsfcrts snjtvvr3l.sk: | ||||||
EtoOG (XeukéxdLs) | 0,2 | 0,2 | 20 | 3 | 2 | 0,3 |
to S 02 ;1wkésis) | 0,2 | 0,2 | 20 | 10 | 2 | o,s |
0-033 (lp?qawss«) | 0,2 | 0,2 | 10 | 3 | 1 | 0,2 |
SS-3, 1 {mátoyAtoákj | 1 | 0,6 | 20 | 12 | S | 0,5 |
KB-V1 (cetrix: msXtlrés rák) | 0,3 | 0,3 | IS | 3 | S | 0,6 |
,é~ 4 §§ (vsso rák) | ... | X,S | ISO | 20 | 20 | 3 |
toSiO Otáőőrák) | 0,7 | 0,1 | 20 | 10 | 3 | 0,1 |
ái Η
ΛΑΑ.·
Paraméter: A kontroj eltelt idő fél“maximális polimerizációja le
20Ö
Reagens Reagens feji
Aj
100
Kontrol18 0
1S(
Spotilon
A ί bS
Epot iIon
v
EpotiIon
Claims (1)
125 ? 6
Spotilon
0 5 —Jt -x
120
106
Spotilon
Mi
5
Spotilon
F
4 9 56
Standard teszt G,9 mg tnbulin/ml és 1 μΜ minta koncentrációval
A polimerizációs kísérlet in vitro kísérlet, melynek során sértés agyából származó tisztított tubulint használunk. A kiértékelést fotörnetriásan végezzük. A polimer!rációt elősegítő anyagok, mint pl. az epotiIonok, csökkentik azt az időt, amely alatt a fél-maximális polimerizaciő végbemegy, vagyis minél rövidébe az idő, annál aktívabb a vegyüiet. W, x, y és z négy önálló kísérlet, a relatív aktivitást az utolsó oszlopban a kontroll %-ában fejezzük ki; a legjobb hatékonyságot itt is a legalacsonyabb értékek jelzik, A hatás-erősség sorrendje meglehetősen pontos egyezést mutat a seittenyés'setekkel végzett kísérlet során tapasztaltakkal.
(b) « AsX^tobmw <e) esXw
«x-íxakfetws'fc b^febs&ényX'tjW a»tM»l é» íwsc&a bfebtfc ttodtolfc ? éss ssskvsaciálix^&n feáfelót kapa
Λ· ·&·
‘ikmtkésit tWfcéáte £eXW#»»á£&«*a «8JY a 8, &a«lafci .ΑSSíSswWí siws
A
SZOLGÁLÓ VÁIJOZ * > v * * > > ♦ ♦» φ * * « φ .»♦ « » x *
Χ . ábra
BgV XAD gyanta eiuábumanak HPLC atalyaise agy Carmen tán© én folyamat végén λ , ábra 1 es e apóexion fai dán óláén. farm ont.lében. A én S epet bion oi agyénak fcatapiaiáao után, Ar nnai i ri gy 48 órás lakúbafás után végeakuk.
ÁWOtATÓM
SZAGA;:A; ;A vOXGYOORODA ? Z.Ö V AAO Q YöZ G y ί ΟΥΥό
Aíf ASOYO 08. Ο.
,vA-?hV\
U] XteKte'noáR
All V O (ÍA'RRN T
Ö8ÁBÁDÁÍ.MX& VföteBöY (RteOA 5 KOVK^RGteteRte'Y te íR sí ’í ábra .8 epotxlon biotranszforeácnősa S: epotxlomjá
AbVOFAl'EÁl
ÉÉÁSáD/p Ab ÉS VÉDJbSY ÉRM'b dVORÉiY
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19647580 | 1996-11-18 | ||
DE19707506 | 1997-02-25 | ||
PCT/EP1997/006442 WO1998022461A1 (de) | 1996-11-18 | 1997-11-18 | Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0000497A2 HUP0000497A2 (hu) | 2000-06-28 |
HUP0000497A3 HUP0000497A3 (en) | 2001-10-29 |
HU229833B1 true HU229833B1 (en) | 2014-09-29 |
Family
ID=26031383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0000497A HU229833B1 (en) | 1996-11-18 | 1997-11-18 | Epothilone d production process, and its use as cytostatic as well as phytosanitary agents |
Country Status (24)
Country | Link |
---|---|
US (6) | US7067544B2 (hu) |
EP (2) | EP1367057B1 (hu) |
JP (1) | JP4274583B2 (hu) |
KR (1) | KR100538095B1 (hu) |
CN (2) | CN100344627C (hu) |
AT (2) | ATE408612T1 (hu) |
AU (1) | AU753546B2 (hu) |
BR (1) | BR9713363B1 (hu) |
CA (1) | CA2269118C (hu) |
CY (1) | CY2542B1 (hu) |
CZ (2) | CZ303422B6 (hu) |
DE (2) | DE59711647D1 (hu) |
DK (2) | DK1367057T3 (hu) |
ES (2) | ES2312695T3 (hu) |
HK (2) | HK1022314A1 (hu) |
HU (1) | HU229833B1 (hu) |
IL (1) | IL129558A (hu) |
NO (1) | NO319984B1 (hu) |
NZ (1) | NZ335383A (hu) |
PL (1) | PL193229B1 (hu) |
PT (2) | PT941227E (hu) |
RU (1) | RU2198173C2 (hu) |
TW (1) | TW408119B (hu) |
WO (1) | WO1998022461A1 (hu) |
Families Citing this family (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2218328T5 (es) | 1995-11-17 | 2011-11-11 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Derivados de epotilón, su preparación y utilización. |
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
US6498257B1 (en) * | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
DE19820599A1 (de) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung |
NZ508326A (en) * | 1998-06-18 | 2003-10-31 | Novartis Ag | A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B |
DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
DE19846493A1 (de) * | 1998-10-09 | 2000-04-13 | Biotechnolog Forschung Gmbh | DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
WO2000031247A2 (en) * | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
CA2356360A1 (en) * | 1998-12-23 | 2000-07-06 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
CN1205208C (zh) * | 1999-02-22 | 2005-06-08 | 生物技术研究股份有限公司 | C-21修饰的环氧噻酮类化合物 |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
WO2000062778A1 (en) | 1999-04-15 | 2000-10-26 | Bristol-Myers Squibb Co. | Cyclic protein tyrosine kinase inhibitors |
EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
US6998256B2 (en) | 2000-04-28 | 2006-02-14 | Kosan Biosciences, Inc. | Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate |
ES2254493T3 (es) * | 2000-04-28 | 2006-06-16 | Kosan Biosciences, Inc. | Produccion heterologa de policetidos. |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
GB0029895D0 (en) * | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
KR100851719B1 (ko) | 2001-01-25 | 2008-08-11 | 브리스톨-마이어스스퀴브컴파니 | 암 치료용 에포틸론 유사체의 투여 방법 |
WO2002058699A1 (en) * | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
CA2434566A1 (en) | 2001-01-25 | 2002-08-15 | Timothy M. Malloy | Parenteral formulation containing epothilone analogs |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
EP1385529A4 (en) | 2001-02-20 | 2007-05-09 | Bristol Myers Squibb Co | TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES |
RU2003128312A (ru) | 2001-02-20 | 2005-02-10 | Бристол-Маерс Сквибб Компани (Us) | Производные эпотилона, используемые для лечения резистентных опухлей |
KR100848197B1 (ko) | 2001-02-27 | 2008-07-24 | 노파르티스 아게 | 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물 |
BR0207675A (pt) | 2001-02-27 | 2004-03-09 | Biotechnolog Forschung Gmbh | Degradação de epotilonas |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
EP1392664A4 (en) | 2001-06-01 | 2005-01-26 | Bristol Myers Squibb Co | EPOTHILONE DERIVATIVES |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
US6884608B2 (en) | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
KR20040078123A (ko) | 2002-01-14 | 2004-09-08 | 노파르티스 아게 | 에포틸론 및 대사길항물질을 포함하는 조합물 |
TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
AU2003218107A1 (en) | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
DE60330651D1 (en) | 2002-03-12 | 2010-02-04 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
WO2003105828A1 (en) | 2002-06-14 | 2003-12-24 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
CA2494742C (en) * | 2002-07-29 | 2015-05-12 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
AU2003260002B2 (en) * | 2002-08-23 | 2010-03-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
GEP20074017B (en) | 2002-09-23 | 2007-01-10 | Bristol Myers Squibb Co | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
WO2004035050A1 (en) * | 2002-10-15 | 2004-04-29 | Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College | Use of epothilone derivatives for the treatment of hyperparathyroidism |
WO2004045518A2 (en) | 2002-11-15 | 2004-06-03 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
CN100359014C (zh) * | 2003-01-28 | 2008-01-02 | 北京华昊中天生物技术有限公司 | 一类新型埃坡霉素化合物及其制备方法和用途 |
US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
EP1559447A1 (en) | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
TWI417092B (zh) | 2004-04-07 | 2013-12-01 | Novartis Ag | Iap抑制劑 |
US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
EP1958625A1 (en) * | 2004-11-18 | 2008-08-20 | Brystol-Myers Squibb Company | Enteric coate bead comprising ixabepilone and preparation thereof |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20080255149A1 (en) | 2005-09-27 | 2008-10-16 | Novartis Ag | Carboxyamine Compounds and Methods of Use Thereof |
JP2009516671A (ja) | 2005-11-21 | 2009-04-23 | ノバルティス アクチエンゲゼルシャフト | mTOR阻害剤を使用する神経内分泌腫瘍処置 |
GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
JP2009532035A (ja) | 2006-03-31 | 2009-09-10 | ブリストル−マイヤーズ スクイブ カンパニー | 微小管安定化剤に対する感受性を決定するためのバイオマーカーおよび方法 |
US20090233905A1 (en) | 2006-04-05 | 2009-09-17 | Gregory Peter Burke | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
BRPI0709750A2 (pt) | 2006-04-05 | 2011-07-26 | Novartis Ag | combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer |
NZ572299A (en) | 2006-05-09 | 2010-07-30 | Novartis Ag | Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof |
CA2664378A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as pi3k lipid kinase inhibitors |
CA2671492A1 (en) | 2006-12-04 | 2008-06-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and cpg rich dna |
CA2677803A1 (en) | 2007-02-08 | 2008-08-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
EP2120900A2 (en) | 2007-02-15 | 2009-11-25 | Novartis AG | Combination of lbh589 with other therapeutic agents for treating cancer |
MX2010010525A (es) | 2008-03-24 | 2010-10-25 | Novartis Ag | Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida. |
EA019033B1 (ru) | 2008-03-26 | 2013-12-30 | Новартис Аг | Ингибиторы дезацетилазы в, основанные на гидроксамате |
CN101362784A (zh) * | 2008-10-06 | 2009-02-11 | 山东大学 | 埃博霉素苷类化合物和以其为活性成分的组合物及其应用 |
WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
JP2012516345A (ja) | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | 星細胞腫治療用置換ベンゾイミダゾール |
EA021011B1 (ru) | 2009-06-26 | 2015-03-31 | Новартис Аг | 1,3-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗОЛИДИН-2-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ Cyp 17 |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
KR20120089643A (ko) | 2009-08-12 | 2012-08-13 | 노파르티스 아게 | 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도 |
JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
EA201200321A1 (ru) | 2009-08-26 | 2012-09-28 | Новартис Аг | Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4 |
MX2012005293A (es) | 2009-11-04 | 2012-06-19 | Novartis Ag | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek. |
EP2509964B1 (en) | 2009-12-08 | 2014-04-30 | Novartis AG | Heterocyclic sulfonamide derivatives |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
JP2013537210A (ja) | 2010-09-16 | 2013-09-30 | ノバルティス アーゲー | 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤 |
CN103442737B (zh) | 2011-01-20 | 2017-03-29 | 得克萨斯系统大学董事会 | Mri标记、递送和提取系统及其制造方法和用途 |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
BR112013031201A2 (pt) | 2011-06-09 | 2017-01-31 | Novartis Ag | derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit |
RU2617402C2 (ru) | 2011-06-10 | 2017-04-25 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
EP2721008B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors |
EA201490164A1 (ru) | 2011-06-27 | 2014-04-30 | Новартис Аг | Твердые формы и соли производных тетрагидропиридопиримидина |
CN102863474A (zh) | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
ES2691650T3 (es) | 2011-09-15 | 2018-11-28 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met |
CN102993239A (zh) | 2011-09-19 | 2013-03-27 | 陈小平 | 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物 |
EP2785717B1 (en) | 2011-11-29 | 2016-01-13 | Novartis AG | Pyrazolopyrrolidine compounds |
EP2794594A1 (en) | 2011-12-22 | 2014-10-29 | Novartis AG | Quinoline derivatives |
PL2794600T3 (pl) | 2011-12-22 | 2018-06-29 | Novartis Ag | Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów |
US20140357633A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
KR20140107573A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
CN104136428A (zh) | 2011-12-23 | 2014-11-05 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
EA201491265A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
US9126979B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
KR101372563B1 (ko) | 2011-12-26 | 2014-03-14 | 주식회사 삼양바이오팜 | 에포틸론 함유물질로부터 에포틸론 a와 b의 추출 및 정제 방법 |
US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
TR201807023T4 (tr) | 2012-05-15 | 2018-06-21 | Novartis Ag | Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. |
EA026559B1 (ru) | 2012-05-15 | 2017-04-28 | Новартис Аг | Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1 |
US9278981B2 (en) | 2012-05-15 | 2016-03-08 | Novartis Ag | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
AU2013261130A1 (en) | 2012-05-15 | 2014-10-23 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
JP6171003B2 (ja) | 2012-05-24 | 2017-07-26 | ノバルティス アーゲー | ピロロピロリジノン化合物 |
WO2013188763A1 (en) | 2012-06-15 | 2013-12-19 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
SI3023415T1 (en) | 2012-10-02 | 2018-01-31 | Gilead Sciences, Inc. | Histone demethylase inhibitors |
US9725477B2 (en) | 2012-11-17 | 2017-08-08 | Beijing Fswelcome Technology Development Co., Ltd | Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino |
TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫-吡啶并-□衍生物之固體形式 |
AU2013359506B2 (en) | 2012-12-10 | 2018-05-24 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
JP6514117B2 (ja) | 2013-02-27 | 2019-05-15 | エピセラピューティクス アーペーエス | ヒストン脱メチル化酵素の阻害剤 |
US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
WO2014198645A1 (en) | 2013-06-11 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015042078A2 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
HUE046816T2 (hu) | 2013-10-11 | 2020-03-30 | Asana Biosciences Llc | Fehérje-polimer-gyógyszer konjugátumok |
EA032231B1 (ru) | 2013-10-11 | 2019-04-30 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
EP3122729A4 (en) | 2014-03-28 | 2017-11-15 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
CA2943824A1 (en) | 2014-03-31 | 2015-10-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
BR112016022499A2 (pt) | 2014-04-03 | 2017-08-15 | Invictus Oncology Pvt Ltd | Produtos terapêuticos combinatórios supramoleculares |
SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
WO2018237262A1 (en) | 2017-06-22 | 2018-12-27 | Mersana Therapeutics, Inc. | METHODS FOR PRODUCING POLYMERIC MATRICES TRANSPORTING MEDICAMENTS, AND PROTEIN-POLYMER-MEDICINE CONJUGATES |
EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
CA3083040A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
CA3099419A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
EP3788032B1 (en) | 2018-05-04 | 2024-01-24 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
JP2022513400A (ja) | 2018-10-29 | 2022-02-07 | メルサナ セラピューティクス インコーポレイテッド | ペプチド含有リンカーを有するシステイン操作抗体-薬物コンジュゲート |
FR3087650B1 (fr) | 2018-10-31 | 2021-01-29 | Bio Even | Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer |
CN115135628A (zh) | 2019-06-17 | 2022-09-30 | 泰克沃尔科斯制药有限公司 | 快速高效点击释放的化合物 |
IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
WO2023031445A2 (en) | 2021-09-06 | 2023-03-09 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
AU2022395626A1 (en) | 2021-11-25 | 2024-05-30 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
AU2022404647A1 (en) | 2021-12-08 | 2024-06-13 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
EP4314031B1 (en) | 2022-02-15 | 2024-03-13 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
WO2024013724A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody-drug conjugates |
WO2024080872A1 (en) | 2022-10-12 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Strained bicyclononenes |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0358606A3 (de) | 1988-09-09 | 1990-10-31 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Mikrobiologisches Verfahren zur Herstellung agrarchemisch verwendbarer mikrobizider makrozyklischer Lactonderivate |
GB8909737D0 (en) | 1989-04-27 | 1989-06-14 | Shell Int Research | Thiazole derivatives |
DE4138042C2 (de) * | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
CA2157190A1 (en) | 1993-03-05 | 1994-09-15 | Wilfried Fischer | Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation |
EP0739339A1 (en) | 1994-01-11 | 1996-10-30 | The Scripps Research Institute | Chemical switching of taxo-diterpenoids between low solubility active forms and high solubility inactive forms |
DE19542986A1 (de) * | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
ES2218328T5 (es) * | 1995-11-17 | 2011-11-11 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Derivados de epotilón, su preparación y utilización. |
DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
DE19636343C1 (de) | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
CN100344627C (zh) * | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
CA2281105A1 (en) * | 1997-02-25 | 1998-09-03 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilones with a modified side chain |
US5828449A (en) | 1997-02-26 | 1998-10-27 | Acuity Imaging, Llc | Ring illumination reflective elements on a generally planar surface |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
US6348551B1 (en) | 1997-04-18 | 2002-02-19 | Studiengesellschaft Kohle Mbh | Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
EP1001951B1 (de) | 1997-07-16 | 2002-09-25 | Schering Aktiengesellschaft | Thiazolderivate, verfahren zur herstellung und verwendung |
DE59814067D1 (de) | 1997-08-09 | 2007-09-06 | Bayer Schering Pharma Ag | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
EP1052974B1 (en) | 1998-02-05 | 2009-05-20 | Novartis AG | Pharmaceutical formulation containing epothilone |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
CA2322157C (en) | 1998-02-25 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
WO2000000485A1 (de) | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
US6410301B1 (en) * | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
PT1140944E (pt) | 1998-12-22 | 2004-01-30 | Novartis Pharma Gmbh | Derivados de epotilona e sua utilizacao como agentes antitumorais |
US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6596875B2 (en) * | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
PL349863A1 (en) | 1999-02-18 | 2002-09-23 | Schering Ag | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
CN1205208C (zh) * | 1999-02-22 | 2005-06-08 | 生物技术研究股份有限公司 | C-21修饰的环氧噻酮类化合物 |
US6211412B1 (en) * | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
PE20010116A1 (es) | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US6489314B1 (en) * | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US6589968B2 (en) * | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
US6906188B2 (en) * | 2001-04-30 | 2005-06-14 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Method for synthesizing epothilones and epothilone analogs |
WO2003029195A1 (fr) * | 2001-09-28 | 2003-04-10 | Sumika Fine Chemicals Co., Ltd. | Intermediaires pour l'elaboration d'un derive de l'epothilone, et leur procede de production |
US6884608B2 (en) * | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
US6921769B2 (en) * | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
GEP20074017B (en) | 2002-09-23 | 2007-01-10 | Bristol Myers Squibb Co | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
-
1997
- 1997-11-18 CN CNB2005100062827A patent/CN100344627C/zh not_active Expired - Lifetime
- 1997-11-18 EP EP03016552A patent/EP1367057B1/de not_active Expired - Lifetime
- 1997-11-18 CZ CZ20041118A patent/CZ303422B6/cs not_active IP Right Cessation
- 1997-11-18 AU AU54837/98A patent/AU753546B2/en not_active Expired
- 1997-11-18 RU RU99113031/04A patent/RU2198173C2/ru active
- 1997-11-18 AT AT03016552T patent/ATE408612T1/de active
- 1997-11-18 ES ES03016552T patent/ES2312695T3/es not_active Expired - Lifetime
- 1997-11-18 DK DK03016552T patent/DK1367057T3/da active
- 1997-11-18 KR KR10-1999-7004302A patent/KR100538095B1/ko not_active IP Right Cessation
- 1997-11-18 CZ CZ0175099A patent/CZ296164B6/cs not_active IP Right Cessation
- 1997-11-18 DE DE59711647T patent/DE59711647D1/de not_active Expired - Lifetime
- 1997-11-18 CN CNB971998140A patent/CN1196698C/zh not_active Expired - Lifetime
- 1997-11-18 IL IL12955897A patent/IL129558A/en not_active IP Right Cessation
- 1997-11-18 PL PL333435A patent/PL193229B1/pl unknown
- 1997-11-18 BR BRPI9713363-9A patent/BR9713363B1/pt not_active IP Right Cessation
- 1997-11-18 PT PT97951233T patent/PT941227E/pt unknown
- 1997-11-18 AT AT97951233T patent/ATE267197T1/de active
- 1997-11-18 WO PCT/EP1997/006442 patent/WO1998022461A1/de active IP Right Grant
- 1997-11-18 JP JP52320898A patent/JP4274583B2/ja not_active Expired - Lifetime
- 1997-11-18 NZ NZ335383A patent/NZ335383A/xx not_active IP Right Cessation
- 1997-11-18 EP EP97951233A patent/EP0941227B2/de not_active Expired - Lifetime
- 1997-11-18 PT PT03016552T patent/PT1367057E/pt unknown
- 1997-11-18 DE DE59712968T patent/DE59712968D1/de not_active Expired - Lifetime
- 1997-11-18 DK DK97951233T patent/DK0941227T5/da active
- 1997-11-18 CA CA2269118A patent/CA2269118C/en not_active Expired - Lifetime
- 1997-11-18 HU HU0000497A patent/HU229833B1/hu unknown
- 1997-11-18 ES ES97951233T patent/ES2221692T5/es not_active Expired - Lifetime
-
1998
- 1998-01-21 TW TW086117334A patent/TW408119B/zh not_active IP Right Cessation
-
1999
- 1999-05-14 NO NO19992338A patent/NO319984B1/no not_active IP Right Cessation
-
2000
- 2000-02-29 HK HK00101272A patent/HK1022314A1/xx not_active IP Right Cessation
-
2004
- 2004-11-12 US US10/988,328 patent/US7067544B2/en not_active Expired - Fee Related
-
2005
- 2005-10-26 CY CY0500058A patent/CY2542B1/xx unknown
-
2006
- 2006-03-24 HK HK06103757A patent/HK1083832A1/xx not_active IP Right Cessation
- 2006-04-27 US US11/412,536 patent/US20060264482A1/en not_active Abandoned
-
2008
- 2008-04-28 US US12/110,781 patent/US20080293784A1/en not_active Abandoned
-
2009
- 2009-03-24 US US12/409,823 patent/US7846952B2/en not_active Expired - Fee Related
- 2009-05-01 US US12/434,078 patent/US7759375B2/en not_active Expired - Fee Related
-
2010
- 2010-12-06 US US12/961,447 patent/US8076490B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU229833B1 (en) | Epothilone d production process, and its use as cytostatic as well as phytosanitary agents | |
ES2218328T5 (es) | Derivados de epotilón, su preparación y utilización. | |
Rivero-Cruz et al. | Conformational behavior and absolute stereostructure of two phytotoxic nonenolides from the fungus Phoma herbarum | |
KR101173510B1 (ko) | 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도 | |
JP2002514649A (ja) | エポチロン誘導体、それらの製造方法、並びにそれらの使用 | |
Höfle et al. | Epothilone AD and their thiazole-modified analogs as novel anticancer agents | |
FI93014B (fi) | Sorafeeni, menetelmä sen valmistamiseksi ja sen käyttö kasvitautien torjumiseksi | |
Fang et al. | Two New Components of the Aspochalasins Produced by Aspergillm sp. | |
KR102012416B1 (ko) | 치마 버섯 균주 배양 추출물을 함유하는 항균성 조성물 및 이의 제조 방법 | |
NZ230596A (en) | Soraphen derivatives, myxobacteria which produce them, and their use for combatting plant diseases | |
CN101177425B (zh) | 一类新型埃坡霉素化合物及其制备方法和用途 | |
JP2005511774A (ja) | 抗菌化合物 | |
CN102101863B (zh) | 新型环氧噻酮化合物及其制备方法和用途 | |
JP5578649B2 (ja) | アクチノマデュラ属に属する新規微生物、その微生物が産生する新規化合物、及びその化合物を有効成分とする医薬 | |
JPH06184157A (ja) | 新規物質及び該物質を生産する微生物 | |
JP2020029406A (ja) | 植物成長調節剤 | |
JP2009510135A (ja) | バーコルデリア・リゾキシナから得られる抗有糸分裂性リゾキシン誘導体、その製造方法及びその使用 | |
JPH01299268A (ja) | 抗真菌性発酵産生物及びその誘導体及びその組成物 | |
JP4224404B2 (ja) | 破骨細胞分化抑制物質 | |
WO1996026199A1 (en) | Active bio-compounds | |
JPH07505781A (ja) | 抗菌的に活性な化合物 | |
JPS58201795A (ja) | 植物抽出物およびそれを有効成分として含有する農園芸用殺菌組成物 |